Next-gen gene editing at ASH

With Casgevy’s approval setting the bar for gene editing technologies in sickle cell disease, data at ASH provide a window into progress by the next wave of companies with editors for hemoglobinopathies. Among them are Editas, which is championing an alternative enzyme technology, and Chinese companies leveraging the country’s streamlined investigator-initiated trial (IIT) pathway.

Presentations at the meeting also highlighted innovations in ex vivo and in vivo hematopoietic cell engineering that could benefit hematological gene engineering products across the board...